(Q34513643)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

22 October 2022

Coronaviruses - drug discovery and therapeutic options (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

respiratory tract infection

1 reference

22 October 2022

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jasper Fuk-Woo Chan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

David Shu-cheong Hui

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yuen Kwok-yung

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

Esam I Azhar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

12 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

7 March 2020

1 May 2016

1 reference

22 October 2022

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

22 October 2022

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

327-347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd.2015.37

7 March 2020

exact match

0 references

cites work

Coronavirus diversity, phylogeny and interspecies jumping

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Interspecies transmission and emergence of novel viruses: lessons from bats and birds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cross-species transmission and emergence of novel viruses from birds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A major outbreak of severe acute respiratory syndrome in Hong Kong

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A cluster of cases of severe acute respiratory syndrome in Hong Kong.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Epidemiologic clues to SARS origin in China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Coronavirus as a possible cause of severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A novel coronavirus associated with severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Index patient and SARS outbreak in Hong Kong

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

SARS-CoV infection in a restaurant from palm civet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Antibodies to SARS coronavirus in civets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Bats are natural reservoirs of SARS-like coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A review of studies on animal reservoirs of the SARS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Spread of MERS to South Korea and China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evidence for camel-to-human transmission of MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Acute middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Taking stock of the first 133 MERS coronavirus cases globally--Is the epidemic changing?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Hospital outbreak of Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Family cluster of Middle East respiratory syndrome coronavirus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

2014 MERS-CoV outbreak in Jeddah--a link to health care facilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East Respiratory Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Advancing priority research on the Middle East respiratory syndrome coronavirus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome vs. the Middle East respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Transmission of MERS-coronavirus in household contacts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe Acute Respiratory Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Medical treatment of viral pneumonia including SARS in immunocompetent adult

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical management and infection control of SARS: lessons learned

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The management of coronavirus infections with particular reference to SARS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Fatal aspergillosis in a patient with SARS who was treated with corticosteroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Use of convalescent plasma therapy in SARS patients in Hong Kong.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human aminopeptidase N is a receptor for human coronavirus 229E

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Protease inhibitors targeting coronavirus and filovirus entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Treatment of SARS with human interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development of a standard treatment protocol for severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Suppression of coronavirus replication by cyclophilin inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

MERS CoV infection in two renal transplant recipients: case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development of a chimeric DNA-RNA hammerhead ribozyme targeting SARS virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Broad-spectrum antiviral therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

MERS-CoV papain-like protease has deISGylating and deubiquitinating activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Antiviral drugs specific for coronaviruses in preclinical development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Design of wide-spectrum inhibitors targeting coronavirus main proteases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Rapid generation of a mouse model for Middle East respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Resistance to enfuvirtide, the first HIV fusion inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of SARS-CoV replication by siRNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Application of siRNA against SARS in the rhesus macaque model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Structure and inhibition of the SARS coronavirus envelope protein ion channel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Structural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein as an Antiviral Target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A broad-spectrum antiviral targeting entry of enveloped viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cure of hookworm infection with a cysteine protease inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

High-frequency ultrasound imaging of the duodenum and colon in patients with symptomatic giardiasis in comparison to amebiasis and healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Effects of chloroquine on viral infections: an old drug against today's diseases?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Current advancements and potential strategies in the development of MERS-CoV vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome: obstacles and prospects for vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evaluation of candidate vaccine approaches for MERS-CoV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development of a transgenic mouse model susceptible to human coronavirus 229E.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Seroconversion to HCoV-NL63 in Rhesus Macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Aetiology: Koch's postulates fulfilled for SARS virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Pneumonia from human coronavirus in a macaque model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Infection with MERS-CoV causes lethal pneumonia in the common marmoset

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Viral loads in clinical specimens and SARS manifestations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A systematic approach to novel virus discovery in emerging infectious disease outbreaks.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Replicative Capacity of MERS Coronavirus in Livestock Cell Lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRD.2015.37

31 March 2020

12 December 2020

Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

TMPRSS2 is an activating protease for respiratory parainfluenza viruses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

SARS--beginning to understand a new virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Severe acute respiratory syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.37

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

31 March 2020

1 reference

12 December 2020

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

1 reference

12 December 2020

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma

1 reference

12 December 2020

[Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China]

1 reference

12 December 2020

State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans

1 reference

12 December 2020

Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.

1 reference

12 December 2020

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

1 reference

12 December 2020

Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication

1 reference

12 December 2020

A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus

1 reference

12 December 2020

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

1 reference

12 December 2020

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.

1 reference

12 December 2020

Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach

1 reference

12 December 2020

SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum

1 reference

12 December 2020

Reverse transcription recombinase polymerase amplification assay for the detection of middle East respiratory syndrome coronavirus

1 reference

12 December 2020

Pancreatic stellate cells: new target in the treatment of chronic pancreatitis

1 reference

12 December 2020

Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2015.37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868298%20AND%20SRC:MED&resulttype=core&format=json